Bluejay Diagnostics Inc
NASDAQ:BJDX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bluejay Diagnostics Inc
Inventory
Bluejay Diagnostics Inc
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bluejay Diagnostics Inc
NASDAQ:BJDX
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Inventory
$2.9B
|
CAGR 3-Years
16%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Inventory
$1.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
13%
|
|
|
Stryker Corp
NYSE:SYK
|
Inventory
$5.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
12%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Inventory
$6.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Inventory
$1.8B
|
CAGR 3-Years
27%
|
CAGR 5-Years
25%
|
CAGR 10-Years
27%
|
|
Bluejay Diagnostics Inc
Glance View
Bluejay Diagnostics, Inc. operates as a diagnostic company. The company is headquartered in Acton, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2021-11-10. The firm is engaged in the developing and marketing minimally invasive point of care (POC) diagnostics tests and devices that provide patients and providers with access to healthcare. The firm offers diagnostic testing in infectious, inflammatory and metabolic diseases by using its Symphony platform. The company focuses on offering solution to the infectious disease, inflammation, and oncology markets. The Company’s ALLEREYE diagnostic test (ALLEREYE) is a POC device that offers healthcare providers a solution for diagnosis of allergic conjunctivitis. The firm's product candidate includes Symphony IL-6 Sepis triage, Symphony IL-6 LDT market, Symphony IL-6 SEPSIS, Symphony hsTNT/I and NT-proBNP. The company is utilizing the platform for detection of sepsis, cancer and other diseases. The company is also developing biomarkers for detection of other diseases, such as cardiac ischemia and congestive heart failure.
